The US Food and Drug Administration has approved imatinib (Gleevec) for the treatment of newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in children.
The US Food and Drug Administration has approved ponatinib (Iclusig) to treat adults with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
The expanded FDA approval of abiraterone acetate (Zytiga) now includes its use prior to chemotherapy in men with metastatic castration-resistant prostate cancer.
The US Food and Drug Administration (FDA) has approved cabozantinib (Cometriq) for the treatment of metastatic medullary thyroid cancer, a rare type of thyroid cancer that makes up about 4% of all cases.
The FDA today approved omacetaxine mepesuccinate (Synribo) for the treatment of adults with chronic myeloid leukemia (CML) who are resistant to other therapies.
AVEO Pharmaceuticals Inc has announced that it has submitted a new drug application for tivozanib to the US Food and Drug Administration for the treatment of metastatic renal cell carcinoma.
Results from a phase Ib/II trial presented at the ESMO 2012 Congress found that a tumor-targeting doxorubicin conjugate, aldoxorubicin (INNO-206), showed activity in relapsed soft-tissue sarcoma patients.
The FDA has approved the multikinase inhibitor regorafenib (Stivarga) to treat patients with colorectal cancer that has metastasized following previous treatment.
The FDA has approved an ultrasound device shown to be capable of detecting small masses in dense breasts. The device is indicated for use in combination with mammography for breast cancer screening.
The FDA has approved the production and use of 11C choline, an agent used to detect recurrent prostate cancer during PET imaging.